Results 51 to 60 of about 72,473 (300)
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical ...
Marwan N. Sabbagh +9 more
doaj +1 more source
S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway [PDF]
, 2012 Peer reviewedPublisher ...
Berg, Daniela +12 more
core +1 more source
Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation. [PDF]
, 2020 In Parkinson's disease, some of the first alpha-synuclein aggregates appear in the olfactory system and the dorsal motor nucleus of the vagus nerve before spreading to connected brain regions.
Brundin, Patrik +3 more
core +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown +6 more
wiley +1 more source
Lewy body disease and dementia with Lewy bodies
Proceedings of the Japan Academy, Series B, 2014 In 1976 we reported our first autopsied case with diffuse Lewy body disease (DLBD), the term of which we proposed in 1984. We also proposed the term "Lewy body disease" (LBD) in 1980. Subsequently, we classified LBD into three types according to the distribution pattern of Lewy bodies: a brain stem type, a transitional type and a diffuse type.
openaire +3 more sources
Advanced Healthcare Materials, EarlyView.This manuscript describes the cultivation of viable microvessels from cryopreserved human brain tissue. When embedded in hydrogels and cultured in microfluidic devices, these microvessels exhibit complex architectures reminiscent of arterioles and capillaries, can be perfused, and display intact barrier function. Collectively, these results demonstrate
Brian J. O'Grady +5 more
wiley +1 more source
Behavioural Neurology, 1990 In cortical Lewy body dementia the distribution of Lewy bodies in the nervous system follows that of Parkinson's disease, except for their greater profusion in the cerebral cortex. The cortical tangles and plaques of Alzheimer pathology are often present,
W. R. G. Gibb
doaj +1 more source
Anosognosia in dementia with Lewy bodies: a systematic review
Arquivos de Neuro-Psiquiatria, 2021 Background: Anosognosia, i.e. lack of awareness of one’s own symptoms, is a very common finding in patients with dementia and is related to neuropsychiatric symptoms and worse prognosis. Although dementia with Lewy bodies (DLB) is the second most common
Victor CALIL +4 more
doaj +1 more source
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. [PDF]
, 2015 BackgroundParkinson's disease (PD) is one of the most common causes of dementia and motor deficits in the elderly. PD is characterized by the abnormal accumulation of the synaptic protein alpha-synuclein (α-syn) and degeneration of dopaminergic neurons ...
Anderson, Scott +4 more
core +2 more sources
Molecular Pathology of Lewy Body Diseases [PDF]
International Journal of Molecular Sciences, 2009 Lewy body diseases are characterized by the presence of Lewy bodies, alpha-synuclein(AS)-positive inclusions in the brain. Since their main component is conformationally modified AS, aggregation of the latter is thought to be a key pathogenic event in these diseases.
Beyer, Katrin +2 more
openaire +3 more sources